Possible options for new pertussis vaccines (Q38195759)

30 August 2017

1 reference

title

Possible options for new pertussis vaccines (English)

1 reference

30 August 2017

Camille Locht

1 reference

30 August 2017

Stanley A Plotkin

1 reference

30 August 2017

Bruce D Meade

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 April 2014

1 reference

Journal of Infectious Diseases

30 August 2017

published in

1 reference

30 August 2017

volume

209 Suppl 1

1 reference

30 August 2017

page(s)

S24-7

1 reference

Pertussis re-emergence in the post-vaccination era

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

The acellular pertussis vaccine trials: an interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Waning protection after fifth dose of acellular pertussis vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Priming with whole-cell versus acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Early Impact of the US Tdap vaccination program on pertussis trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

The benefits of using diverse animal models for studying pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Nonhuman primate model of pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Nomenclature for immune correlates of protection after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

New pertussis vaccination approaches: en route to protect newborns?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Re-emergence of pertussis: what are the solutions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT531

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIT531

1 reference

30 August 2017

1 reference